Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Phase 1

Recruiting

• Conditions: Lymphoblastic Leukemia; Lymphoblastic Leukemia in Children; CAR; Lymphoblastic Leukemia, Acute, Childhood; Lymphoblastic Leukemia, Acute Adult
• Interventions: Biological: Phase II; Biological: Phase I

• Registration Number: NCT05429905
• Lead Sponsor: KK Women's and Children's Hospital

Brief Summary

The purpose of this study is to deliver dual-targeting CAR-T cell therapy (CART 2219.1) as a salvage treatment to patients with relapsed/refractory B-lineage leukaemia in place of stem cell transplant or irradiation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-12-16
• Study First Submitted QC: 2022-06-20
• Study First Posted: 2022-06-23
• Study Start: 2022-07-18
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-07
• Last Update Posted: 2023-03-09
• Primary Completion: 2024-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

All Cohorts:

• Age 2 to 75 years
• Absolute blood CD3+ T cell count ≥100/μl
• ECOG performance score of ≤2 if >16 years old, or Lansky performance score of >50 if ≤16 years old at screening
• Patients and/or parents must give their written informed consent/assent.
• Patients have relapsed/refractory B-lineage acute lymphoblastic leukaemia, includes persistent minimal residual disease (MRD)

Cohort 1 (Phase I): Relapsed/Refractory B-ALL

• Patients must have relapsed/refractory (r/r) B-lineage ALL meeting one of the following disease-specific criteria:

  • Patients with r/r ALL with >5% blasts in BM (M2 or M3) after at least one standard chemotherapy and one salvage regimen who are ineligible for allogeneic stem cell transplant (alloSCT) or have refractory disease activity (e.g. persistent MRD in bone marrow) precluding alloSCT, or
  • Patients with Ph+ ALL if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have r/r disease after treatment including TKI, or
  • Patients who have relapsed post-allogeneic HSCT and are at least 100 days post-transplant, with no evidence of active GVHD, > 6 weeks post donor lymphocyte infusion (DLI) and no longer taking immunosuppressive agents for at least 30 days prior to enrolment.
  • Patients who have relapsed after prior CAR-T therapy who are not eligible for stem cell transplant and have < 5% circulating CAR-T prior to apheresis

• Patients with refractory/relapsed combined extramedullary ALL are eligible. This includes patients with combined CNS-2 (<5 WBC/μl CSF, with blasts on cytospin) or CNS-3 (>5 WBC/ul CSF, with blasts on cytospin) disease and patients with combined testicular relapse.

Cohort 2 (Phase II): B-ALL with persistent MRD (High Risk B-ALL)

• Patients must have persistent MRD >0.1% blasts after frontline induction chemotherapy or >0.01% blasts after consolidation therapy.

Cohort 3 (Phase II): Relapsed/Refractory Extramedullary B-ALL

• Patients with testicular leukaemia confirmed on biopsy
• Patients with CNS-3 B-ALL or Leptomeningeal disease
• Patients with combined bone marrow and extramedullary relapse (as defined in Cohort 1) are eligible.

Exclusion Criteria

All Cohorts:

• Blasts are negative for both CD22 and CD19 on flow cytometry or immunohistochemistry, defined as < 10% of blasts staining positive for CD22 and CD19 respectively [IBFM 2016 Consensus Guidelines].

• Current autoimmune disease, or history of autoimmune disease with potential CNS involvement

• Active clinically significant CNS dysfunction (including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, paralysis)

• History of an additional malignancy other than non-melanoma skin cancer or carcinoma in situ unless disease free for ≥3 years.

• Pulmonary function: Patients with pre-existing severe lung disease (FEV1 or FVC < 65%) or an oxygen requirement of >28% O2 supplementation or active pulmonary infiltrates on chest X-ray at the time scheduled for T cell infusion

• Cardiac function: Fractional shortening <28% or left ventricular ejection fraction <50% by echocardiography

• Renal function: Creatinine clearance <50 mL/min/1.73 m2

• Liver function: Patients with a serum bilirubin >3 times upper limit of normal or an AST or ALT > 5 times upper limit of normal, unless due to leukemic liver infiltration in the estimation of the investigator

• Rapidly progressive disease that in the estimation of the investigator would compromise ability to complete study therapy

• Active Hepatitis B (HBsAg positive) or Hepatitis C (PCR positive), or known infection with human immunodeficiency virus (HIV)

• Pregnant or nursing (lactating) women

• In relation to prior therapy:

  • Use of immunotherapy, cell-based or other investigational treatment within 30 days of CAR-T infusion

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 2 (High MRD)	Phase II	Patients with B-ALL with high MRD after induction therapy or after consolidation therapy in replacement of stem cell transplant
Cohort 3 (Extramedullary ALL)	Phase II	Patients with testicular or central nervous system B-ALL in replacement of radiation
Cohort 1 (Dose-escalation)	Phase I	Dose-finding and dose expansion cohort for intravenous autologous anti-CD22/CD19 CAR-T using a relapsed refractory B-ALL cohort.

Primary Outcome Measures

Name	Time	Method
Recommended Phase II Dose (Phase I, Cohort 1)	30 days	The RP2D will be the dose level at which \< 1 DLT in 3 patients or \< 2 DLT in 6 patients is observed in both the adult and paediatric dose escalation stratas.
12-month Leukaemia Free Survival (Phase II, Cohort 2 and 3)	12 months	Survival with Marrow MRD \<0.01% by flow cytometry
Number of patients with dose-limiting toxicities (Phase I, Cohort 1)	30 days	To be DLTs, adverse events must be suspected to be secondary to CAR-T cell infusion, occur during the first 30 days after infusion and meet at least one of the following criteria: 1. Grade ≥ 3 non-hematologic toxicities, with the following exceptions: * Laboratory abnormalities without associated symptomatology or clinical consequence that resolve in less than 7 days; * Grade ≤ 2 cytokine release syndrome; * Grade 3 cytokine release syndrome that improves to grade ≤ 2 within 3 days of intervention; * Grade 3 neurotoxicity that resolves to grade 2 or less within 3 days.; * Laboratory abnormalities compatible with tumor lysis syndrome; 2. Grade ≥ 4 hematologic toxicities that persist at a grade ≥ 3 for \>21 days.; Cytokine release syndrome and immune-effector cell associated neurotoxicity syndrome (ICANS) are graded according to ASTCT consensus grading. Adverse events are graded according to CTCAE version 5.0.

Secondary Outcome Measures

Name	Time	Method
Overall Response Rate (ORR)	3 months	Percentage of patients in the study who have a partial or complete response to the treatment within 3 months.
Duration of CAR-T persistence	Up to 24 months	Duration of measurable CAR-T above detection limits in peripheral blood and/or marrow
Duration of Response (DOR)	Up to 24 months	Duration of complete remission (CR or CR with partial/incomplete haematological recovery)
Overall Survival Rate (OS)	12 months	Percentage of patients in the study who are alive 12 months after CAR-T infusion.

Trial Locations

Locations (1)

KK Women's and Children's hospital; 🇸🇬 Singapore, Singapore